# Ginkgo Bioworks **Source:** https://geo.sig.ai/brands/ginkgo-bioworks **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** ginkgobioworks.com **Last Updated:** 2026-04-14 ## Summary Synthetic biology platform for cell engineering; public company restructuring after SPAC overvaluation, shifting focus to government biosecurity contracts. ## Company Overview Ginkgo Bioworks is a synthetic biology platform company that provides cell programming services to the agricultural, pharmaceutical, food, and industrial chemicals industries, helping customers design and manufacture biological products using engineered microorganisms. Founded in 2008 by MIT researchers and headquartered in Boston, Ginkgo went public via SPAC merger in September 2021 at a $15 billion valuation — one of the largest biotech-related SPAC transactions ever. Ginkgo's platform combines automated biology labs (called Foundries), proprietary genetic parts libraries (the Codebase), and data analysis to dramatically reduce the cost and time to engineer cells for industrial applications. Customers pay Ginkgo to design strains that produce target compounds — enzymes, proteins, novel molecules — using a platform fee plus royalty model. The company has collaborated with Bayer (agriculture), Sumitomo Chemical, Ginkgo Crop Protection, and defense agencies on biological manufacturing programs. In 2025, Ginkgo has undergone significant restructuring after its SPAC valuation proved unsustainably high relative to revenue growth. The company announced major layoffs of over 50% of its workforce in 2023-2024 and sold or wound down several subsidiary businesses to reduce cash burn. Revenue has been concentrated in government biosecurity contracts (Ginkgo Biosecurity) rather than commercial synthetic biology, raising questions about the commercial viability of its original platform vision. Ginkgo's 2025-2026 survival strategy focuses on right-sizing costs, expanding government biosecurity revenue, and identifying the core platform capabilities worth preserving. ## Frequently Asked Questions ### What is Ginkgo Bioworks? Ginkgo Bioworks (NYSE: DNA) is the leading synthetic biology platform founded in 2009 and based in Boston, Massachusetts. The company engineers organisms for applications in pharmaceuticals, agriculture, and industrial chemicals, and is working toward adjusted EBITDA breakeven by the end of 2026. ### What products and services does Ginkgo Bioworks offer? Ginkgo Bioworks offers a cell programming platform, organism engineering, biosecurity services, enzyme optimization, and pharmaceutical development services. These solutions leverage synthetic biology to create custom-engineered organisms for various applications. ### Who are Ginkgo Bioworks' target customers? Ginkgo Bioworks serves customers in the pharmaceuticals, agriculture, and industrial chemicals sectors. The company also works with government agencies, as evidenced by their BARDA contract. ### When was Ginkgo Bioworks founded? Ginkgo Bioworks was founded in 2009 and participated in Y Combinator's W14 batch. ### Where is Ginkgo Bioworks located? Ginkgo Bioworks is based in Boston, Massachusetts. ### Is Ginkgo Bioworks publicly traded? Yes, Ginkgo Bioworks is publicly traded on the New York Stock Exchange under the ticker symbol DNA. The company maintains a $517M cash position as of their latest reporting. ### What are Ginkgo Bioworks' recent financial achievements? Ginkgo Bioworks generated $227M in revenue in 2024 and reduced quarterly cash burn by 75% in Q3 2025. The company maintains a strong cash position of $517M and restructured their Google Cloud contract, saving over $100M. ### What technology does Ginkgo Bioworks use? Ginkgo Bioworks operates a synthetic biology platform that programs and engineers cells and organisms. Their technology enables applications across pharmaceuticals, agriculture, and industrial chemicals through organism engineering. ### How can I work with or contact Ginkgo Bioworks? Ginkgo Bioworks is located in Boston, Massachusetts and trades publicly on NYSE under the ticker DNA. Specific contact information is not provided in the available company information. ### What are Ginkgo Bioworks' recent developments? In November 2025, Ginkgo Bioworks was awarded a BARDA contract worth up to $22.2M. The company has also significantly improved its financial position by reducing quarterly cash burn by 75% in Q3 2025 and restructuring its Google Cloud contract to save over $100M. ## Tags healthtech, b2b, public, north-america --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*